Skip to main content
. Author manuscript; available in PMC: 2013 Oct 9.
Published in final edited form as: Ann Intern Med. 2011 Jul 19;155(2):69–79. doi: 10.7326/0003-4819-155-2-201107190-00002

Table 3.

Effect of Instituting an Upper Age Limit to Screen for the Lynch Syndrome Among Persons With Newly Diagnosed Colorectal Cancer

Upper Age to Screen for the Lynch Syndrome Persons With Newly Diagnosed Colorectal Cancer Who Are Eligible for Screening, %* Prevalence of the Lynch Syndrome Among Persons Who Are Eligible for Screening, %* Persons With the Lynch Syndrome Included Among Persons Eligible for Screening, %* Prevalence of the Lynch Syndrome Among Persons Not Eligible for Screening, %* Discounted Incremental Cost per Life-Year Gained With the IHC With BRAF Testing Strategy, $
50 y 11 16 57 1.5 27 900
60 y 27 9 78 0.9 33 800
70 y 49 6 91 0.5 44 200
None 100 3 100 – 88 700

IHC = immunohistochemistry.

*

Derived from data in references 15 and 20. We assumed a prevalence of the Lynch syndrome of 3% among all persons with newly diagnosed colorectal cancer.